Overview

K-924 Phase III Long Term Study

Status:
Completed

Trial end date:
2021-08-07

Target enrollment:

Participant gender:

Summary

A Multicenter, Open-label Study to Evaluate 52 weeks long term Efficacy and Safety of K-924 in Patients with hypercholesterolemia who were treated with pitavastatin 2 mg or 4 mg.

Phase:

Phase 3

Details

Lead Sponsor:

Kowa Company, Ltd.

Treatments:

Pitavastatin